<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231025059847N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-09</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the analgesia effect of pudendal block with placebo after pelvic floor prolapse surgeries</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the analgesia effect of perineal nerve blockage with marcaine with placebo after pelvic floor prolapse surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>25</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73389</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study has two arms. First arm: pudendal block with marcaine. The second arm is the control group with placebo.
In this study, random allocation will be done, the type of random allocation is block and the randomization unit is individual. Blocks of 4 will be used for random allocation. The randomization tool is the following online software:
https://www.sealedenvelope.com/simple-randomiser/v1/lists
Therefore, people will be randomly placed in one of two groups. In this study, due to the fact that the intervention is determined for the surgeon and the patient and is an open-label trial, blinding is not possible, but the analyzers of A and B will be blinded.
Concealment will be done in the study, Blinding description: Blinding: the researcher who performs the analysis at the end is unaware of the allocation of the groups. So the study is one-side blind.
The patient side is not blind.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Pelvic floor prolapse surgeries.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Women undergoing pelvic floor prolapse surgery, 30-80 years old, for whom pudendal block is performed as follows: 2 cc of Marcaine 7.5 mg/ml aspen group of companies inside the vagina, 1 cm lateral and behind the ischial spines. Intervention 2: Control group: Women undergoing pelvic floor prolapse surgery, 30-80 years old, for whom normal saline is administered in the same way as pudendal block after surgery: 2 cc of normal saline 0.9% inside the vagina, 1 cm lateral and behind the ischial spines.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After unrecognizing the participants, patient's demographic data, study protocol and main outcome information will be shared.

When:
The access period starts 3 months after the results are published

To whom:
All doctors and researchers working in the field of obstetrics and gynecology

Conditions:
Any data analysis and use of documents in the field of obstetrics and gynecology is allowed

Where to obtain:
The email address of the project manager: Hamide Nematian 
hnematian6173@gmail.com

How to obtain:
Email to the project manager and receive the required data within a month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamide Nematian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini hospital complex, Keshavarz Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733134</zip>
        <telephone>+98 21 6119 0000</telephone>
        <email>hnematian6173@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tahereh Eftekhar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini hospital complex, Keshavarz Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733134</zip>
        <telephone>+98 21 6119 0000</telephone>
        <email>eftkhart@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women undergoing pelvic floor prolapse surgery</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>80 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of chronic pelvic pain
History of hypersensitivity to blocking drugs, narcotics or analgesics
Chronic use of analgesics or narcotics
Patients suffering from liver or kidney problems
Patients with simultaneous abdominal or laparoscopic surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N81.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Incomplete uterovaginal prolapse</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Women undergoing pelvic floor prolapse surgery, 30-80 years old, for whom pudendal block is performed as follows: 2 cc of Marcaine 7.5 mg/ml aspen group of companies inside the vagina, 1 cm lateral and behind the ischial spines.</i_keyword>
      <i_keyword>Control group: Women undergoing pelvic floor prolapse surgery, 30-80 years old, for whom normal saline is administered in the same way as pudendal block after surgery: 2 cc of normal saline 0.9% inside the vagina, 1 cm lateral and behind the ischial spines.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain level after surgery. Timepoint: The day after the surgery. Method of measurement: Visual analogue scale.</prim_outcome>
      <prim_outcome>Nausea. Timepoint: The day after the surgery. Method of measurement: Asking the patient how often she feels nausea.</prim_outcome>
      <prim_outcome>Number of analgesics used. Timepoint: The day after the surgery. Method of measurement: Checking the number of analgesics requests in the file.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamide Nematian</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-10</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences, Imam Khomeini hospital complex</contact_name>
        <contact_address>Imam Khomeini Hospital Complex, Keshavarz Boulevard Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
